Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn’s disease treated with infliximab

Pharmacogenomics Journal

Volumn 2, Issue 2, 2002, Pages 127-136

  Mascheretti, S ^a   Hampe, J ^a   Kuhbacher T ^a   Herfarth, H ^b   Krawczak, M ^a,c   Folsch U R ^a   Schreiber, S ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Autoimmunity; Clinical trial; Crohn's disease; Inflammatory bowel disease; Infliximab; TNF

Indexed keywords

ARGININE; AZATHIOPRINE; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ALLELE; ANALYTICAL ERROR; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG RESPONSE; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MARKER GENE; METHODOLOGY; MUTANT; PATIENT CARE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; WILD TYPE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CROHN DISEASE; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; MUTATION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; STATISTICS, NONPARAMETRIC;

EID: 0036367145     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500091     Document Type: Article

References (52)

1. The transmission/disequilibrium test detects cosegregation and linkage
2. Mapping genes for polygenic disorders: Consideration for study design in the complex trait of inflammatory bowel disease
3. National Cooperative Crohn's Disease Study: Results of drug treatment
4. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
5. Tumor necrosis factor alpha and interleukin 1-beta in relapse of Crohn's disease
6. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
7. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
8. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
9. Preliminary results of early clinical trails with the fully human anti-TNFalpha monoclonal antibody D2E7
10. The relationship between infliximab treatment and lymphoma in Crohn's disease
11. Anti tumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results and safety in inflammatory bowel disease
12. Clinical efficacy of treatment with infliximab in a German multicenter, prospective, open-label trial in refractory Crohn's disease
13. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF alpha and activates immune effector functions
14. Molecular cloning and expression of the human 55kD tumor necrosis factor receptor
15. Structure of the human TNF receptor 1 (p6O) gene (TNFR1) and localisation to chromosome 12pl3
16. Cloning and partial characterisation of the promoter for the human p55 tumor necrosis factor (TNF) receptor
17. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins
18. Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor
19. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor
20. Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterisation
21. Physical mapping and genomic structure of the human TNFR2 gene
22. No independent association between a tumor necrosis factor-alpha promotor region polymorphism and insulin-dependent diabetes mellitus
23. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles
24. Infliximab for the treatment of fistulas in patients with Crohn's disease
25. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD)
26. A polymorphism that affects OCT-1 bidning to the TNF promoter region is associated with severe malaria
27. Crohn's disease is associated with novel polymorphisms in the 5′- flanking region of the tumor necrosis factor gene
28. An MspA1 I polymorphism in exon 1 of the human TNF receptor type I (pS5) gene
29. Genetic variants in the tumor necrosis factor receptor 1 gene in patients with MS
30. Polymorphic analysis of the high-affinity tumor necrosis factor receptor 2
31. Model-free analysis and permutation tests for allelic associations
32. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
33. Mechanisms in failure of infliximab for Crohn's disease
34. A genome-wide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort
35. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci
36. Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses
37. Linkage of inflammatory bowel disease to human chromosome 6p
38. Relevance of the tumor necrosis factor alpha (TNF-alpha) - 308 promoter polymorphism in TNF alpha gene regulation
39. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor concentrations and outcome of patients with severe sepsis
40. Effect of a polymorphism in the tumor necrosis factor alpha promoter on transcriptional activation
41. ANCA pattern and LTA haplotype relationships to clinical responses to anti-TNF antibody treatment in Crohn's disease
42. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease
43. Response to anti-TNFa treatment is associated with the TNFa-308* 1 allele
44. Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease
45. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: Evidence for epistasis between 1p and IBD1
46. Association of tumor necrosis factor receptor 2 (TNFR2) polyrnorphism with susceptibility to systemic lupus erythematosus
47. Tumor necrosis factor alpha 5′-flanking region, tumor necrosis factor receptor II, and HLA-DRB1 polymorphisms in Japanese patients with rheumatoid arthritis
48. Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus
49. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation
50. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis
51. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12